

Yasutoshi Koga

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5584950/publications.pdf>

Version: 2024-02-01

74
papers

6,329
citations

147801

31
h-index

79698

73
g-index

75
all docs

75
docs citations

75
times ranked

8652
citing authors

#	ARTICLE	IF	CITATIONS
1	Mitochondrial DNA Deletions in Progressive External Ophthalmoplegia and Kearns-Sayre Syndrome. <i>New England Journal of Medicine</i> , 1989, 320, 1293-1299.	27.0	1,012
2	Mitochondrial diseases. <i>Nature Reviews Disease Primers</i> , 2016, 2, 16080.	30.5	1,001
3	Primary LAMP-2 deficiency causes X-linked vacuolar cardiomyopathy and myopathy (Danon disease). <i>Nature</i> , 2000, 406, 906-910.	27.8	865
4	Evidence of ROS generation by mitochondria in cells with impaired electron transport chain and mitochondrial DNA damage. <i>Mitochondrion</i> , 2007, 7, 106-118.	3.4	426
5	Recombination via flanking direct repeats is a major cause of large-scale deletions of human mitochondrial DNA. <i>Nucleic Acids Research</i> , 1990, 18, 561-567.	14.5	345
6	Growth differentiation factor 15 as a useful biomarker for mitochondrial disorders. <i>Annals of Neurology</i> , 2015, 78, 814-823.	5.3	212
7	MELAS: A nationwide prospective cohort study of 96 patients in Japan. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 2012, 1820, 619-624.	2.4	206
8	Endothelial dysfunction in MELAS improved by l-arginine supplementation. <i>Neurology</i> , 2006, 66, 1766-1769.	1.1	172
9	Findings in muscle in complex I (NADH coenzyme Q reductase) deficiency. <i>Annals of Neurology</i> , 1988, 24, 749-756.	5.3	109
10	MELAS and l-arginine therapy. <i>Mitochondrion</i> , 2007, 7, 133-139.	3.4	107
11	Chronic progressive external ophthalmoplegia: A correlative study of mitochondrial DNA deletions and their phenotypic expression in muscle biopsies. <i>Journal of the Neurological Sciences</i> , 1990, 100, 63-69.	0.6	106
12	GDF15 is a novel biomarker to evaluate efficacy of pyruvate therapy for mitochondrial diseases. <i>Mitochondrion</i> , 2015, 20, 34-42.	3.4	103
13	MELAS and l-arginine therapy: pathophysiology of stroke-like episodes. <i>Annals of the New York Academy of Sciences</i> , 2010, 1201, 104-110.	3.8	98
14	Effects of l-arginine on the acute phase of strokes in three patients with MELAS. <i>Neurology</i> , 2002, 58, 827-828.	1.1	97
15	Cdk5rap1-Mediated 2-Methylthio Modification of Mitochondrial tRNAs Governs Protein Translation and Contributes to Myopathy in Mice and Humans. <i>Cell Metabolism</i> , 2015, 21, 428-442.	16.2	95
16	Taurine supplementation for prevention of stroke-like episodes in MELAS: a multicentre, open-label, 52-week phase III trial. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019, 90, 529-536.	1.9	79
17	Mitochondrial DNA and RNA processing in MELAS. <i>Annals of Neurology</i> , 1996, 40, 172-180.	5.3	74
18	Heterogeneous presentation in A3243G mutation in the mitochondrial tRNA ^{Leu} (UUR) gene. <i>Archives of Disease in Childhood</i> , 2000, 82, 407-411.	1.9	66

#	ARTICLE	IF	CITATIONS
19	Molecular pathology of MELAS and l-arginine effects. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 2012, 1820, 608-614.	2.4	61
20	International Workshop: Neuromuscular Disorders, 2017, 27, 1126-1137.	0.6	58
21	Therapeutic regimen of l-arginine for MELAS: 9-year, prospective, multicenter, clinical research. <i>Journal of Neurology</i> , 2018, 265, 2861-2874.	3.6	56
22	Therapeutic potential of pyruvate therapy for mitochondrial diseases. <i>Mitochondrion</i> , 2007, 7, 399-401.	3.4	51
23	Focal cytochrome c oxidase deficiency in various neuromuscular diseases. <i>Journal of the Neurological Sciences</i> , 1989, 91, 207-213.	0.6	49
24	Analysis of cybrids harboring MELAS mutations in the mitochondrial tRNA ^{Leu} (UUR) gene. <i>Muscle and Nerve</i> , 1995, 18, S119-S123.	2.2	48
25	Fine mapping of mitochondrial RNAs derived from the mtDNA region containing a point mutation associated with MELAS. <i>Nucleic Acids Research</i> , 1993, 21, 657-662.	14.5	45
26	Beneficial effect of pyruvate therapy on Leigh syndrome due to a novel mutation in PDH E1 α gene. <i>Brain and Development</i> , 2012, 34, 87-91.	1.1	45
27	Use of single strand conformation polymorphism analysis to detect point mutations in human mitochondrial DNA. <i>Journal of the Neurological Sciences</i> , 1992, 111, 222-226.	0.6	39
28	Differential expression of genes specifying two isoforms of subunit VIa of human cytochrome c oxidase. <i>Gene</i> , 1992, 119, 307-312.	2.2	38
29	Efficacy of pyruvate therapy in patients with mitochondrial disease: A semi-quantitative clinical evaluation study. <i>Molecular Genetics and Metabolism</i> , 2014, 112, 133-138.	1.1	34
30	Fatal hypertrophic cardiomyopathy associated with an A8296G mutation in the mitochondrial tRNA ^{Lys} gene. <i>Human Mutation</i> , 2000, 15, 382-382.	2.5	32
31	Mitochondrial tRNA gene mutations in patients having mitochondrial disease with lactic acidosis. <i>Mitochondrion</i> , 2006, 6, 29-36.	3.4	32
32	Inappropriate intracranial hemodynamics in the natural course of MELAS. <i>Brain and Development</i> , 2008, 30, 100-105.	1.1	32
33	A Novel Myc-target Gene, mimitin, That Is Involved in Cell Proliferation of Esophageal Squamous Cell Carcinoma*. <i>Journal of Biological Chemistry</i> , 2005, 280, 19977-19985.	3.4	31
34	The mitochondrial DNA C3303T mutation can cause cardiomyopathy and/or skeletal myopathy. <i>Journal of Pediatrics</i> , 1999, 135, 197-202.	1.8	30
35	Tissue specificity in cytochrome c oxidase deficient myopathy. <i>Journal of the Neurological Sciences</i> , 1989, 92, 193-203.	0.6	29
36	A new sequence variant in mitochondrial DNA associated with high penetrance of Russian Leber hereditary optic neuropathy. <i>Mitochondrion</i> , 2005, 5, 194-199.	3.4	29

#	ARTICLE	IF	CITATIONS
37	Noonan syndrome, moyamoya-like vascular changes, and antiphospholipid syndrome. <i>Pediatric Neurology</i> , 2004, 31, 364-366.	2.1	26
38	Extensive screening system using suspension array technology to detect mitochondrial DNA point mutations. <i>Mitochondrion</i> , 2010, 10, 300-308.	3.4	25
39	Arginine therapy in mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes. <i>Current Opinion in Clinical Nutrition and Metabolic Care</i> , 2020, 23, 17-22.	2.5	25
40	Increased mitochondrial processing intermediates associated with three tRNA ^{Leu} (UUR) gene mutations. <i>Neuromuscular Disorders</i> , 2003, 13, 259-262.	0.6	24
41	Pyruvate therapy for Leigh syndrome due to cytochrome c oxidase deficiency. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 2010, 1800, 313-315.	2.4	24
42	Single-fiber analysis of mitochondrial A3243G mutation in four different phenotypes. <i>Acta Neuropathologica</i> , 2000, 99, 186-190.	7.7	21
43	Biomarkers and clinical rating scales for sodium pyruvate therapy in patients with mitochondrial disease. <i>Mitochondrion</i> , 2019, 48, 11-15.	3.4	21
44	Effect of l-arginine on synaptosomal mitochondrial function. <i>Brain and Development</i> , 2008, 30, 238-245.	1.1	19
45	Pyruvate Improved Insulin Secretion Status in a Mitochondrial Diabetes Mellitus Patient. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016, 101, 1924-1926.	3.6	19
46	Glycogenic hepatopathy and non-alcoholic fatty liver disease in type 1 diabetes patients. <i>Pediatrics International</i> , 2013, 55, 806-807.	0.5	18
47	New TRPM6 mutation and management of hypomagnesaemia with secondary hypocalcaemia. <i>Brain and Development</i> , 2015, 37, 292-298.	1.1	18
48	P1148A in fibrillin-1 is not a mutation leading to Shprintzen-Goldberg syndrome. <i>Human Mutation</i> , 1997, 10, 326-327.	2.5	17
49	Evaluation of Systemic Redox States in Patients Carrying the MELAS A3243G Mutation in Mitochondrial DNA. <i>European Neurology</i> , 2012, 67, 232-237.	1.4	17
50	l-Arginine intervention at hyper-acute phase protects the prolonged MRI abnormality in MELAS. <i>Journal of Neurology</i> , 2016, 263, 1666-1668.	3.6	16
51	GDF-15, a mitochondrial disease biomarker, is associated with the severity of multiple sclerosis. <i>Journal of the Neurological Sciences</i> , 2019, 405, 116429.	0.6	14
52	Defects in muscle fiber growth in fatal infantile cytochrome c oxidase deficiency. <i>Brain and Development</i> , 1988, 10, 223-230.	1.1	12
53	MELAS exhibits dominant negative effects on mitochondrial RNA processing. <i>Annals of Neurology</i> , 1998, 43, 835-835.	5.3	11
54	Long-Term Analysis of Differentiation in Human Myoblasts Repopulated with Mitochondria Harboring mtDNA Mutations. <i>Biochemical and Biophysical Research Communications</i> , 1999, 266, 179-186.	2.1	11

#	ARTICLE	IF	CITATIONS
55	Successful Glycemic Control Decreases the Elevated Serum FGF21 Level without Affecting Normal Serum GDF15 Levels in a Patient with Mitochondrial Diabetes. <i>Tohoku Journal of Experimental Medicine</i> , 2016, 239, 89-94.	1.2	11
56	Progressive cytochrome c oxidase deficiency in a case of Leigh's encephalomyelopathy. <i>Journal of the Neurological Sciences</i> , 1990, 95, 63-76.	0.6	9
57	Inter- and/or Intra-organ distribution of mitochondrial C3303T or A3243G mutation in mitochondrial cytopathy. <i>Acta Neuropathologica</i> , 2001, 101, 179-184.	7.7	8
58	Successful treatment of infantile-onset ACAD9-related cardiomyopathy with a combination of sodium pyruvate, beta-blocker, and coenzyme Q ₁₀ . <i>Journal of Pediatric Endocrinology and Metabolism</i> , 2019, 32, 1181-1185.	0.9	7
59	A new diagnostic indication device of a biomarker <sc>growth differentiation factor 15</sc> for mitochondrial diseases: From laboratory to automated inspection. <i>Journal of Inherited Metabolic Disease</i> , 2021, 44, 358-366.	3.6	7
60	Mitochondrial DNA depletion syndrome with a mutation in SLC25A4 developing epileptic encephalopathy: A case report. <i>Brain and Development</i> , 2022, 44, 56-62.	1.1	5
61	BCS1L mutations produce Fanconi syndrome with developmental disability. <i>Journal of Human Genetics</i> , 2022, 67, 143-148.	2.3	5
62	A case of combined 21 α -hydroxylase deficiency and CHARGE syndrome featuring micropenis and cryptorchidism. <i>Molecular Genetics & Genomic Medicine</i> , 2019, 7, e730.	1.2	4
63	A two-day-old hyperthyroid neonate with thyroid hormone resistance born to a mother with well-controlled Graves's disease: a case report. <i>Journal of Medical Case Reports</i> , 2012, 6, 246.	0.8	3
64	Early Onset of Diabetes Mellitus Accelerates Cognitive Decline in Japanese Patients with Mitochondrial Myopathy, Encephalopathy, Lactic Acidosis, and Stroke-Like Episodes. <i>Tohoku Journal of Experimental Medicine</i> , 2016, 238, 311-316.	1.2	3
65	ADHD-like behavior in a patient with hypothalamic hamartoma. <i>Brain and Development</i> , 2016, 38, 145-148.	1.1	3
66	Cytochrome c oxidase deficiency with acute onset and rapid recovery. <i>Pediatric Neurology</i> , 1990, 6, 330-332.	2.1	2
67	Growth differentiation factor 15 as a useful biomarker of heart failure in young patients with unrepaired congenital heart disease of left to right shunt. <i>Journal of Cardiology</i> , 2020, 75, 697-701.	1.9	2
68	Biochemistry of mitochondria, life and intervention 2010. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 2012, 1820, 551-552.	2.4	1
69	Developmental delay and failure to thrive in a 7-month-old baby boy with spontaneous transient Graves's thyrotoxicosis: a case report. <i>Journal of Medical Case Reports</i> , 2016, 10, 219.	0.8	1
70	Biomarker changes associated with clinical symptoms in MELAS patient. <i>Neurology and Clinical Neuroscience</i> , 2019, 7, 344-346.	0.4	1
71	Temple syndrome diagnosed in an adult patient with clinical autism spectrum disorder. <i>Clinical Case Reports (discontinued)</i> , 2019, 7, 15-18.	0.5	1
72	Temporal changes and control variables of growth differentiation factor 15 levels during the first week of life in hospitalised newborn infants. <i>Mitochondrion</i> , 2021, 61, 25-30.	3.4	1

#	ARTICLE	IF	CITATIONS
73	Mitochondrial research in Asia: A step for the mito-global conference. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 2020, 1864, 129638.	2.4	0
74	Growth differentiation factor 15 as a novel diagnostic and therapeutic marker for autoimmune hepatitis. <i>Scientific Reports</i> , 2022, 12, .	3.3	0